Alpha Synuclein Immunotherapy is an important component in the neurobiology of neurodegenerative diseases. This page provides detailed information about its structure, function, and role in disease processes.
Therapeutic Category: Disease-Modifying Therapies | Immunotherapy [1]
Target: α-Synuclein protein aggregates [2]
Indications: Parkinson's Disease, Multiple System Atrophy, Dementia with Lewy Bodies [3]
Status: Clinical Development (Phase 1-3) [4]
α-Synuclein-targeting immunotherapies represent one of the most promising disease-modifying approaches for Parkinson's disease (PD) and related synucleinopathies. These therapies aim to reduce or eliminate pathological α-synuclein aggregates in the brain through active vaccination or passive antibody administration. The rationale stems from the central role of α-synuclein misfolding and aggregation in the pathogenesis of these neurodegenerative disorders. [5]
The therapeutic strategy leverages the immune system to target extracellular α-synuclein oligomers and fibrils, which are believed to propagate pathology between neurons and contribute to neuroinflammation. By clearing these toxic species, immunotherapies aim to slow or halt disease progression—a goal that has eluded the field for decades. [6]
α-Synuclein is a 140-amino acid protein encoded by the SNCA gene, predominantly expressed in presynaptic terminals of neurons. Under pathological conditions, α-synuclein undergoes misfolding and aggregation, forming toxic oligomers and fibrils that constitute Lewy bodies and Lewy neurites—hallmark inclusions in Parkinson's disease, dementia with Lewy bodies, and multiple system atrophy. [7]
The "prion-like" propagation hypothesis suggests that misfolded α-synuclein can spread from cell to cell, template the misfolding of endogenous protein, and thereby disseminate pathology throughout the nervous system. This extracellular release of α-synuclein species makes them accessible to antibody-mediated clearance, providing the therapeutic rationale for immunotherapy approaches. [8]
Active vaccination stimulates the patient's own immune system to produce antibodies against α-synuclein. This approach offers potential advantages including long-lasting immunity with periodic boosters and lower treatment costs. [9]
PD01A, developed by Affiris AG, was the first α-synuclein vaccine to enter clinical trials. It consists of a synthetic peptide mimicking the N-terminal region of α-synuclein, designed to induce antibodies that recognize pathological forms of the protein while sparing normal physiological function. [10]
Clinical Development: [11]
ACI-35, developed by AC Immune and Lundbeck, uses a liposome-based vaccine platform with a phosphorylated serine-129 (pS129) epitope. Targeting pS129 is strategically advantageous because this post-translational modification is highly enriched in pathological α-synuclein inclusions, potentially improving specificity for disease-associated species. [12]
Clinical Development: [13]
Passive immunotherapy involves direct administration of monoclonal antibodies against α-synuclein, offering precise epitope targeting and avoiding variable individual immune responses. [14]
Cinpanemab (BIIB054) is a fully human monoclonal antibody developed by Biogen that binds to the N-terminal region of α-synuclein, targeting a conformational epitope present on toxic oligomers.
Clinical Development:
Prasinezumab is a humanized monoclonal antibody developed by Roche that targets the C-terminal region of α-synuclein. The C-terminal region is highly immunogenic and contains epitopes specific to pathological conformations.
Clinical Development:
ABBV-0805 (formerly 2-79 and BAN-0805) is a monoclonal antibody targeting α-synuclein fibrils, developed through collaboration between AbbVie and BioArctic.
Clinical Development:
The choice of epitope significantly impacts therapeutic potential and safety:
| Epitope Region | Target | Advantages | Considerations |
|---|---|---|---|
| N-terminal | N-terminus (aa 1-30) | Targets physiological and pathological forms; may block seeding | Potential for off-target effects |
| C-terminal | C-terminus (aa 110-140) | Conformational specificity; less physiological interaction | May miss early oligomeric species |
| pS129 | Phosphorylated Ser-129 | High disease specificity; targets pathological inclusions | Requires phosphorylation to be present |
α-Synuclein immunotherapies employ multiple mechanisms to exert neuroprotective effects:
FcγR-mediated phagocytosis: Antibodies bind to extracellular α-synuclein, engaging Fc gamma receptors on microglia and macrophages to enhance clearance
Complement activation: Antibody binding can trigger the complement cascade, leading to opsonization and removal of pathological species
Neutralization of seeding activity: Antibodies prevent the propagation of misfolded α-synuclein by neutralizing templating activity
Reduction of neuroinflammation: By clearing extracellular aggregates, immunotherapies may reduce microglial activation and associated neurotoxicity
| Therapy | Trial | Patients | Key Findings |
|---|---|---|---|
| PD01A | NCT01885494 | 32 PD | Safe; antibody responders showed CSF α-syn↓ |
| ACI-35 | NCT03272166 | 48 PD | Robust pS129 antibodies; good safety |
| Cinpanemab | NCT02459886 | 48 PD | Dose-dependent PK; target engagement |
| Prasinezumab | NCT02157714 | 40 PD | 86% CSF free α-syn↓ at highest dose |
| ABBV-0805 | NCT04145050 | 24 PD | Safe; target engagement confirmed |
| Therapy | Trial | Patients | Outcome |
|---|---|---|---|
| Cinpanemab | SPARK | 311 PD | Primary endpoint not met; post-hoc signals |
| Prasinezumab | PASADENA | 316 PD | Primary not met; motor progression ↓ in subgroups |
Key biomarkers used to assess target engagement and therapeutic response:
One of the fundamental challenges for all α-synuclein immunotherapies is achieving sufficient brain penetration. The blood-brain barrier (BBB) limits antibody delivery to approximately 0.1-0.5% of plasma concentrations reaching the brain. Strategies under development include:
Achieving specificity for pathological α-synuclein species while avoiding interference with the physiological function of the protein remains challenging. The N-terminal region targeted by some antibodies overlaps with functional protein domains involved in synaptic vesicle regulation.
Active vaccination can induce variable antibody responses across individuals, and repeated administrations may lead to immune tolerance. Passive antibodies carry minimal immunogenicity risk but require repeated infusions.
The failure of several Phase 2 trials highlights challenges in:
Future directions include combining α-synuclein immunotherapy with:
The field continues to evolve with several promising developments:
Bridi et al. Alpha-Synuclein Antibodies in Clinical Trials (2024). 2024. ↩︎
Bousset et al. Structural insights into α-synuclein aggregation (2023). 2023. ↩︎
Schlossmacher et al. α-Synuclein vaccination in PD (2022). 2022. ↩︎
Weihofen et al. Engineering α-synuclein antibodies (2023). 2023. ↩︎
Ciechanover & Kwon, Passive immunotherapy for synucleinopathies (2024). 2024. ↩︎
Zhang et al. FcγR-mediated clearance of α-synuclein (2023). 2023. ↩︎
Merchant et al. Cinpanemab Phase 2 SPARK results (2023). 2023. ↩︎
Pagano et al. Prasinezumab Phase 2 PASADENA results (2024). 2024. ↩︎
Bergström et al. ABBV-0805 first-in-human study (2023). 2023. ↩︎
Emadi et al. Anti-α-synuclein antibodies blocking propagation (2022). 2022. ↩︎
Sardi et al. CNS delivery strategies for antibodies (2024). 2024. ↩︎
Lahiri et al. Biomarkers in α-synuclein immunotherapy trials (2023). 2023. ↩︎
Cook et al. α-Synuclein seeding assays as biomarkers (2024). 2024. ↩︎
Pujol et al. Prodromal α-synuclein immunotherapy (2023). 2023. ↩︎